Common use of Sublicense Fees and Royalties Clause in Contracts

Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts [***] percent ([***]%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. All other provisions of the Agreement remain unchanged and in full force and effect. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxx X. Xxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxx X. Xxxxx Xxxxxx X. Xxxxxxx Name Name Senior Director, University Development Executive Vice President Title Title 12/23/97 12/29/97 Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A is hereby amended to include: • Patent application entitled: “[***]” Continuation in Part of U.S. patent No.: [***], Filed [***], Notice of Allowance [***]. • Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application jointly owned with [***], entitled: “[***]”, Serial No.: [***], Filed [***] • Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application entitled: “[***]”, U.S. patent No. [***], Issued [***], Divisional Application of U.S. patent No. [***] All other provisions of the Agreement remain unchanged and in full force and effect. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxxxx Xxxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxxxx Xxxxxx Xxxxxx X. Xxxxxxx Name Name Executive Vice President and Associate Xxxxxxx for Research Chief Operating Officer Title Title Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC AMENDMENT NO. 3 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit X. Xxxxx’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. All other provisions of the Agreement as amended remain in full force and effect.

Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts [***] fourteen percent ([***]14%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. All other provisions of the Agreement remain unchanged and in full force and effect. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxx X. Xxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxx X. Xxxxx Xxxxxx X. Xxxxxxx Name Name Senior Director, University Development Executive Vice President Title Title 12/23/97 12/29/97 Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY — -- PARATEK PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A is hereby amended to include: • Patent application entitled: “"[***]” " Continuation in Part of U.S. patent No.: [***], Filed [***], Notice of Allowance [***]. • Provisional patent application entitled: “"[***]”", Serial No.: [***], Filed [***] • Patent application jointly owned with [***], entitled: “"[***]”", Serial No.: [***], Filed [***] • Provisional patent application entitled: “"[***]”", Serial No.: [***], Filed [***] • Patent application entitled: “"[***]”", Serial No.: [***], Filed [***] • Patent application entitled: “"[***]”", U.S. patent No. [***], Issued [***], Divisional Application of U.S. patent No. [***] All other provisions of the Agreement remain unchanged and in full force and effect. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxxxx Xxxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxxxx Xxxxxx Xxxxxx X. Xxxxxxx Name Name Executive Vice President and Associate Xxxxxxx for Research Chief Operating Officer Title Title 7/31/98 7/31/98 Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC AMENDMENT NO. 3 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit X. Xxxxx’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. All other provisions of the Agreement as amended remain in full force and effect.

Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts Licensor the percentage specified below of any lump sum fee that is not an earned royalty, any fixed fee, license fee, milestone payment, unearned portion of any minimum royalty payment, joint marketing fee, intellectual property cross license, and any other property, consideration or thing of value given or exchanged as compensation for a sublicense (collectively, “Sublicense Income”). All such consideration received by Licensee shall be fully auditable by Licensor. If a Sublicensee purchases equity in Licensee in connection with the grant of a sublicense, Licensee and Licensor shall discuss in good faith to determine whether such equity investment was or was not purchased as compensation for the sublicense grant. Licensee shall not receive from Sublicensee(s) anything of value in lieu of cash payments in consideration for any sublicense under this Agreement without the express prior written permission of Licensor. Any non-cash consideration, including, without limitation, equity in other companies or equity investments in Licensee, received by the Licensee from any Sublicensee(s) will be valued at its Fair Market Value as of the date of receipt by Licensee. If additional technologies owned or licensed by Licensee are included in a sublicense agreement that grants rights under this Agreement, the parties hereto will reasonably allocate value among the Patent Rights and the other technologies included in the sublicense and the Sublicense Income percentages set forth below shall be adjusted accordingly, resulting in the Sublicense Income percentages below being applied only to the portion of the total license value that is allocated to the Patent Rights, provided that in no event shall the value allocated to the Patent Rights be less than % of the total value of the Patent Rights and such other technologies. Additional technologies owned or licensed by Licensee are deemed to contribute no value if (1) they are a product, process or usage that falls within the scope of any Valid Claim and (2) the filing date of the Patent Rights predates the filing date of the additional Licensee owned or licensed patent rights included in the sublicense. Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. KUCTC-Reata Confidential [***] Project Status at Time of Sublicense Sublicense Income Percentage [***] [***] percent ([***]%) of that portion of any sublicense issue fees or license maintenance fees Sublicense Income received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) ] percent of any royalty payments Sublicense Income received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. All other provisions of the Agreement remain unchanged and in full force and effect. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxx X. Xxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxx X. Xxxxx Xxxxxx X. Xxxxxxx Name Name Senior Director, University Development Executive Vice President Title Title 12/23/97 12/29/97 Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A is hereby amended to include: • Patent application entitled: “[***]” Continuation in Part of U.S. patent No.: [***], Filed [***], Notice of Allowance [***]. • Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application jointly owned with [***], entitled: “[***]”, Serial No.: [***], Filed percent of Sublicense Income received by Licensee) [***] • Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application entitled: “[***]”, Serial No.: [***], Filed percent of Sublicense Income received by Licensee) [***] • Patent application entitled: “[***]”, U.S. patent No. [***], Issued [***], Divisional Application of U.S. patent No. [***] All other provisions percent of the Agreement remain unchanged and in full force and effect. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxxxx Xxxxxx By: /s/ Xxxxxx X. Xxxxxxx (signatureSublicense Income received by Licensee) (signature) Xxxxxxxx Xxxxxx Xxxxxx X. Xxxxxxx Name Name Executive Vice President and Associate Xxxxxxx for Research Chief Operating Officer Title Title Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary ] [***] percent of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC AMENDMENT NO. 3 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A and all amendments and modifications are deleted and replaced in their entirety Sublicense Income received by the attached Exhibit X. Xxxxx’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. All other provisions of the Agreement as amended remain in full force and effect.Licensee)

Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts [***] fourteen percent ([***]14%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product. All other provisions of the Agreement remain unchanged and in full force and effect. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxx X. Xxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxx X. Xxxxx Xxxxxx X. Xxxxxxx Name Name Senior Director, University Development Executive Vice President Title Title 12/23/97 12/29/97 Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A is hereby amended to include: • Patent application entitled: “[***]” Continuation in Part of U.S. patent No.: [***], Filed [***], Notice of Allowance [***]. • Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application jointly owned with [***], entitled: “[***]”, Serial No.: [***], Filed [***] • Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application entitled: “[***]”, Serial No.: [***], Filed [***] • Patent application entitled: “[***]”, U.S. patent No. [***], Issued [***], Divisional Application of U.S. patent No. [***] All other provisions of the Agreement remain unchanged and in full force and effect. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxxxx Xxxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxxxx Xxxxxx Xxxxxx X. Xxxxxxx Name Name Executive Vice President and Associate Xxxxxxx for Research Chief Operating Officer Title Title Date Date Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC AMENDMENT NO. 3 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit X. Xxxxx’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. All other provisions of the Agreement as amended remain in full force and effect.